Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK ALK V1180L |
Therapy | Lorlatinib |
Indication/Tumor Type | lung small cell carcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK V1180L | lung small cell carcinoma | predicted - sensitive | Lorlatinib | Case Reports/Case Series | Actionable | In a clinical case study, Lorbrena (lorlatinib) treatment resulted in tumor shrinkage after 5 months, with decrease in the size of intracranial and pulmonary lesions, in a patient with transformed small cell lung cancer from lung adenocarcinoma harboring EML4-ALK and ALK V1180L (PMID: 37907052). | 37907052 |
PubMed Id | Reference Title | Details |
---|---|---|
(37907052) | Transformation of NSCLC to SCLC harboring EML4-ALK fusion with V1180L mutation after alectinib resistance and response to lorlatinib: A case report and literature review. | Full reference... |